EGFR/HER2-IN-8 (compound 34) is an inhibitor of EGFR/HER2 and DHFR with IC50 values of 0.45, 0.244 and 5.669 μM for EGFR, HER2 and DHFR, respectively. EGFR/HER2-IN-8 can be used in the cancer research that exhibits anticancer activity against several cancer cell lines with high safety profile and selectivity indices [1].

EGFR/HER2-IN-8 (0-100 μM; 72 h) shows highly potent anticancer activity to HepG2, MCF 7, HCT-116, PC-3 and Hela cell lines and exhibits selective cytotoxicity against cancer cell lines rather than normal cell line [1]. Cell Cytotoxicity Assay [1] Cell Line: HepG2 hepatocellular carcinoma, MCF 7 breast cancer, HCT-116 colorectal carcinoma, PC-3 prostate, Hea cervical epithelioid carcinoma cell lines and WI-38 fetal lung fibroblast cells Concentration: 0-100 μM Incubation Time: 72 hours Result: Exibited more potent cytotoxicity than SOR towards HepG2, MCF 7, HCT-116, PC-3 and Hela cell lines with IC 50 s of 7.34, 5.19, 9.23, 18.5 and 13.02 μM, respectively. Showed weak cytotoxic activity against WI-38 cell line with an IC 50 value of 67.25 μM, and possessed best selectivity indices towards MCF-7 breast cancer cell line.